Orally inhaled drug products are a combination of aerosol generating devices with different principles and corresponding drug forms. It is the first-choice therapy for prevention and treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease(COPD). Orally inhaled drug products not only have technical challenges in the formulation development, but also have many difficulties in their use. This study summarizes the recent research progress of orally inhaled drug products in improving patient compliance, overcoming delivery dose limitations, improving atomization by controlling particle characteristics, and expanding the scope of treatment, as well as the development of relevant regulations and guidelines. The innovations in process, formulation, device, standard and treatment field are reviewed, hoping to provide some references for researches on orally inhaled products.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |